[ARCHIVED] Adherence & Retention
Emergence of Multiclass Drug–Resistance in HIV‐2 in Antiretroviral‐Treated Individuals in Senegal: Implications for HIV‐2 Treatment in Resouce‐Limited West Africa
The efficacy and the experience with various ARV therapy regimens for HIV‐2 infection remains limited.
This study is part of an ongoing prospective longitudinal cohort study of ARV therapy for HIV‐2 infection in Senegal. The study included 23 patients on NRTI and PI (indinavir) based regimens, assessed mutations predictive of resistance in HIV‐2 and analyzed correlates of ARV resistance.
52% of the patients had genetic evidence of resistance to at least one class of ARV, and 30% had resistance to both NRTIs and PIs. Patients with detectable resistance had significantly higher viral loads than those without such resistance yet their viral loads were relatively low.
The study raises questions about the usefulness of viral-load monitoring for assessing the development of resistance and virologic failure in HIV-2 and calls for more studies to improve the management of HIV-2 infection.
Attached resource:
-
Emergence of Multiclass Drug–Resistance in HIV‐2 in Antiretroviral‐Treated Individuals in Senegal: Implications for HIV‐2 Treatment in Resouce‐Limited West Africa (external URL) Link leads to: http://www.journals.uchicago.edu/doi/abs/10.1086/596504
Summary: The efficacy and the experience with various ARV therapy regimens for HIV‐2 infection remains limited.
This study is part of an ongoing prospective longitudinal cohort study of ARV therapy for HIV‐2 infection in Senegal. The study included 23 patients on NRTI and PI (indinavir) based regimens, assessed mutations predictive of resistance in HIV‐2 and analyzed correlates of ARV resistance.
52% of the patients had genetic evidence of resistance to at least one class of ARV, and 30% had resistance to both NRTIs and PIs. Patients with detectable resistance had significantly higher viral loads than those without such resistance yet their viral loads were relatively low.
The study raises questions about the usefulness of viral-load monitoring for assessing the development of resistance and virologic failure in HIV-2 and calls for more studies to improve the management of HIV-2 infection.Source: Clinical Infectious Diseases
Publication Date: January 14, 2009
Language: English
Keywords: Monitoring & Measurement, Publications & Research
Edit Comment Text